Skip to content

Nuestra Misión

The Lone Star Bleeding Disorders Foundation se dedica al tratamiento y cura de los trastornos hemorrágicos relacionados con la hemofilia, las complicaciones de esos trastornos y sus tratamientos, así como a mejorar la calidad de vida de todos los afectados mediante la promoción y apoyo de la investigación, la abogacía, educación y otros servicios.

News from HFA

  • Scholarship Recipient: Michael Potanin

    2023 HFA Educational Scholarship Johns Hopkins University, Maryland I am honored to have been chosen as a recipient of the HFA Educational Scholarship. This recognition provides immense support to me as I pursue my education and career goals. As a hemophiliac who has personally experienced the challenges of living with a genetic disorder, I am The post Scholarship Recipient: Michael Potanin appeared first on Hemophilia Federation of America.

  • Scholarship Recipient: Porus Pavri

    2023 HFA Educational Scholarship Rutgers University, New Jersey As an individual with hemophilia, my journey has been shaped by both challenges and determination. These experiences have propelled me towards pursuing a business major and setting ambitious future goals. I believe that the intersection of my personal circumstances and academic aspirations is a unique space where The post Scholarship Recipient: Porus Pavri appeared first on Hemophilia Federation of America.

  • Blog: Random Thoughts from a Venerable Hemophiliac 

    At 73 and retired, I can look back on life, and wonder how I got to where I am.  Seventy-three is old. You appreciate social security, Medicare, pensions, and the occasional days where arthritis isn’t winning the joint battle.  You appreciate your high school girlfriend who became your wife of 52 years, your adult sons and The post Blog: Random Thoughts from a Venerable Hemophiliac  appeared first on Hemophilia Federation of America.

  • Novo Nordisk Announces Supply Shortage

    Novo Nordisk today announced an important update about the Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated 3000 IU vial size.  From Novo Nordisk: In May 2023, Novo Nordisk launched the Rebinyn® 3000 IU vial size, and the demand for this vial size has outpaced our expectations. This has resulted in a temporary shortage that will lead The post Novo Nordisk Announces Supply Shortage appeared first on Hemophilia Federation of America.

  • Word from Washington: January 2024

    On January 16, the U.S. Department of Health and Human Services withdrew its appeal in the litigation over HHS’s copay accumulator adjuster regulation. Patient groups including HFA applauded this latest development in the lawsuit.  As a reminder, patient groups led by the HIV + Hepatitis Policy Institute had filed suit against HHS, challenging its 2021 The post Word from Washington: January 2024 appeared first on Hemophilia Federation of America.